Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ROIV 
Roivant Sciences Ltd (ROIV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ROIV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $17
1 Year Target Price $17
| 6 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.96% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.61B USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 10 | Beta 1.15 | 52 Weeks Range 8.73 - 14.47 | Updated Date 09/14/2025 |
52 Weeks Range 8.73 - 14.47 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12839.72% |
Management Effectiveness
Return on Assets (TTM) -12.59% | Return on Equity (TTM) -18.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5211517941 | Price to Sales(TTM) 413.85 |
Enterprise Value 5211517941 | Price to Sales(TTM) 413.85 | ||
Enterprise Value to Revenue 224.32 | Enterprise Value to EBITDA 0.74 | Shares Outstanding 682881984 | Shares Floating 417616330 |
Shares Outstanding 682881984 | Shares Floating 417616330 | ||
Percent Insiders 26.13 | Percent Institutions 76.8 |
Upturn AI SWOT
Roivant Sciences Ltd
Company Overview
History and Background
Roivant Sciences Ltd. was founded in 2014 by Vivek Ramaswamy. It is a biopharmaceutical company focused on acquiring and developing promising drug candidates, often those abandoned or deprioritized by larger pharmaceutical companies. Roivant's strategy involves creating 'Vants,' separate companies focused on specific therapeutic areas or drug candidates, each with its own management and specialized focus.
Core Business Areas
- Drug Development: Roivant identifies and acquires promising drug candidates, often in late-stage development, that have been overlooked or deprioritized by larger pharmaceutical companies. It then develops these candidates through clinical trials and seeks regulatory approval.
- Vant Creation: Roivant creates separate companies (Vants) focused on specific therapeutic areas or drug candidates. This decentralized structure allows for specialized expertise and focused management of each program.
- Commercialization: Following regulatory approval, Roivant commercializes its drugs, often through partnerships or its own commercial infrastructure.
Leadership and Structure
Matt Gline is the CEO of Roivant Sciences. The company operates with a decentralized structure, with various 'Vants' managed independently but under the Roivant umbrella. The Board of Directors guides overall strategy and governance.
Top Products and Market Share
Key Offerings
- VTAMA (tapinarof): VTAMA is a topical cream approved for the treatment of plaque psoriasis in adults. Developed and marketed by Dermavant Sciences, a Roivant company. Competitors include topical corticosteroids, vitamin D analogs, and other topical treatments for psoriasis from companies like Amgen (ENBREL), AbbVie (HUMIRA), and LEO Pharma (Enstilar).
- RVT-3101 (TL1A Antibody): RVT-3101 is a potential treatment for inflammatory bowel disease (IBD). Licensed to Pfizer. Phase 3 trials underway. Competitors include other IBD treatments from companies like Johnson & Johnson (REMICADE), AbbVie (HUMIRA), and Takeda (ENTYVIO).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, stringent regulatory requirements, and intense competition. The market is driven by unmet medical needs, aging populations, and advancements in science and technology.
Positioning
Roivant Sciences aims to disrupt the traditional pharmaceutical model by focusing on undervalued assets and employing a decentralized, technology-driven approach. Its competitive advantage lies in its ability to identify and efficiently develop promising drug candidates that larger companies may have overlooked.
Total Addressable Market (TAM)
The total pharmaceutical market is valued at over $1 trillion. Roivant targets specific disease areas with unmet needs, allowing it to address significant segments of the overall market. The TAM for IBD and Psoriasis markets are estimated to be in the billions of dollars.
Upturn SWOT Analysis
Strengths
- Innovative business model (Vant structure)
- Strong leadership team
- Efficient drug development process
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Reliance on successful acquisition and development of drug candidates
- Dependence on funding and capital markets
- Potential for clinical trial failures
- Competition from established pharmaceutical companies
Opportunities
- Acquisition of additional promising drug candidates
- Expansion into new therapeutic areas
- Development of new technologies and platforms
- Strategic partnerships with other companies
Threats
- Regulatory hurdles and delays
- Clinical trial failures
- Competition from other pharmaceutical companies
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- AbbVie (ABBV)
- Pfizer (PFE)
- Amgen (AMGN)
Competitive Landscape
Roivant is a disruptor, while competitors are established giants. Roivant is more agile but has fewer resources. The company relies on efficient and effective partnerships.
Major Acquisitions
Silicon Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 450
- Strategic Rationale: To enhance drug discovery and development capabilities using computational physics-based platform.
Growth Trajectory and Initiatives
Historical Growth: Roivant's growth has been driven by the acquisition and development of new drug candidates and the successful advancement of its Vants.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline products and the ability to secure additional funding and partnerships.
Recent Initiatives: Recent initiatives include licensing deals with major pharmaceutical companies, advancements in clinical trials, and expansion into new therapeutic areas.
Summary
Roivant Sciences operates with an innovative model for drug development by leveraging specialized 'Vants'. Successful acquisitions of drug candidates and advancement in clinical trials are working well. However, clinical trial failures, reliance on capital markets and competition from large pharmaceutical companies remain a risk. Strategic partnerships and a diversified pipeline are crucial for future success, along with an ability to develop partnerships well.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Roivant Sciences website
- SEC Filings
- Company Press Releases
- Analyst Reports
- Industry News Sources
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is an estimate and may not be precise. Financial data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Roivant Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-01 | CEO & Director Mr. Matthew Gline | ||
Sector Healthcare | Industry Biotechnology | Full time employees 750 | Website https://roivant.com |
Full time employees 750 | Website https://roivant.com | ||
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.